Cardiff Oncology (CRDF) Soars 2.10% on Promising Drug Trial Results

Cardiff Oncology (CRDF) shares surged 2.10% today, marking the fifth consecutive day of gains, with a total increase of 18.40% over the past five days. The share price reached its highest level since March 2025, with an intraday gain of 3.89%.

The strategy of buying CRDF shares after they reach a recent high and holding for one week resulted in poor performance over the past five years. The strategy yielded a return of -31.96%, with a Sharpe ratio of -0.17, indicating significant risk and negative returns. The maximum drawdown was -79.34%, and the volatility was 86.14%, suggesting that the strategy carried high risk and resulted in substantial losses.

Cardiff Oncology's recent stock price surge can be largely attributed to the promising results of their Onvansertib drug in the treatment of colorectal cancer. The ongoing Phase 2 trials have shown encouraging outcomes, which has significantly boosted investor confidence in the company's prospects. This positive trend reflects the market's optimism regarding the potential success of Onvansertib, a drug that has shown promise in clinical trials.

Investors are closely monitoring the progress of Onvansertib, as its success could pave the way for further advancements in cancer treatment. The positive results from the Phase 2 trials have not only driven the stock price higher but also reinforced the company's position as a leader in oncology research. The market's response to these developments underscores the potential impact of Onvansertib on the broader healthcare sector, making Cardiff Oncology a stock to watch in the coming months.